Survival outcomes in invasive lobular carcinoma compared to oestrogen receptor-positive invasive ductal carcinoma

TY - JOUR

T1 - Survival outcomes in invasive lobular carcinoma compared to oestrogen receptor-positive invasive ductal carcinoma

AU - Timbres, Jasmine

AU - Moss, Charlotte

AU - Mera, Anca

AU - Haire, Anna

AU - Gillett, Cheryl

AU - Van Hemelrijck, Mieke

AU - Sawyer, Elinor

N1 - Funding Information: The authors thank the Breast Cancer Genetics, KHP Cancer Biobank, and Translational Oncology and Urology Research teams at King?s College London for support on this study. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/6/2

Y1 - 2021/6/2

N2 - Invasive lobular breast cancer (ILC) accounts for 10–15% of breast cancers and has distinct characteristics compared with the more common invasive ductal carcinoma (IDC). Studies have shown that ILC may be less sensitive to chemotherapy than IDC, with lower rates of complete pathological response after neo-adjuvant chemotherapy, but it is not clear how this affects long-term survival. Patients at Guy’s and St Thomas’ NHS Foundation Trust between 1975 and 2016 diagnosed with ER+ IDC or ER+ ILC were eligible for inclusion. Kaplan–Meier plots and Cox proportional-hazards regression models were used for analysis. There was no difference in overall survival comparing ER+ ILC to ER+ IDC (OR: 0.94, 95% CI: 0.83, 1.04) with a median follow-up time of 8.3 years compared to 8.4 years in IDC. However, ER+HER2− ILC had worse survival compared to ER+HER2− IDC in those that received chemotherapy (OR: 1.46, 95% CI: 1.06, 2.01). Here, median follow-up time was 7.0 years in ILC compared to 8.1 years in IDC. These results indicate worse overall survival after chemotherapy (neo-adjuvant and adjuvant) in ILC compared to ER+HER2− IDC even when correcting for tumour grade, age, size, and nodal involvement, but validation is needed in a larger study population.

AB - Invasive lobular breast cancer (ILC) accounts for 10–15% of breast cancers and has distinct characteristics compared with the more common invasive ductal carcinoma (IDC). Studies have shown that ILC may be less sensitive to chemotherapy than IDC, with lower rates of complete pathological response after neo-adjuvant chemotherapy, but it is not clear how this affects long-term survival. Patients at Guy’s and St Thomas’ NHS Foundation Trust between 1975 and 2016 diagnosed with ER+ IDC or ER+ ILC were eligible for inclusion. Kaplan–Meier plots and Cox proportional-hazards regression models were used for analysis. There was no difference in overall survival comparing ER+ ILC to ER+ IDC (OR: 0.94, 95% CI: 0.83, 1.04) with a median follow-up time of 8.3 years compared to 8.4 years in IDC. However, ER+HER2− ILC had worse survival compared to ER+HER2− IDC in those that received chemotherapy (OR: 1.46, 95% CI: 1.06, 2.01). Here, median follow-up time was 7.0 years in ILC compared to 8.1 years in IDC. These results indicate worse overall survival after chemotherapy (neo-adjuvant and adjuvant) in ILC compared to ER+HER2− IDC even when correcting for tumour grade, age, size, and nodal involvement, but validation is needed in a larger study population.

KW - Breast cancer

KW - Chemotherapy

KW - Cohort study

KW - Ductal

KW - Lobular

KW - Retrospective

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85108059854&partnerID=8YFLogxK

U2 - 10.3390/cancers13123036

DO - 10.3390/cancers13123036

M3 - Article

AN - SCOPUS:85108059854

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 12

M1 - 3036

ER -